Condition
Pyrotinib
Total Trials
3
Recruiting
1
Active
1
Completed
0
Key Insights
Highlights
No notable highlights available yet
Clinical Risk Assessment
Based on trial outcomes
Moderate Risk
Score: 50/100
Termination Rate
0.0%
0 terminated out of 3 trials
Late-Stage Pipeline
0%
0 trials in Phase 3/4
Results Transparency
0%
0 of 0 completed with results
Key Signals
Data Visualizations
Phase Distribution
3Total
Not Applicable (1)
P 2 (2)
Trial Status
Unknown1
Recruiting1
Not Yet Recruiting1
Clinical Trials (3)
Showing 3 of 3 trials
NCT06495541Not ApplicableNot Yet Recruiting
The Real World Study of Pyrotinib in the Treatment of Advanced Breast Cancer With HER2 Positive
NCT06832904Phase 2Recruiting
Neoadjuvant Chemotherapy Plus Pyrotinib and Trastuzumab for HER2-positive Breast Cancer (NEOTORCH-BREAST05)
NCT04605575Phase 2Unknown
Pyrotinib Plus Vinorelbine in Participants With HER2-positive Previously Treated Locally Advanced or Metastatic Breast Cancer
Showing all 3 trials